Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Inks Cancer Biomarker Deal with Hutchinson Cancer Center

NEW YORK, Sept. 14 (GenomeWeb News) - Invitrogen will use its ProtoArray protein microarrays to develop diagnostic and screening tools for cancer under a collaboration with the Fred Hutchinson Cancer Research Center, the partners announced yesterday.

Invitrogen said it would apply its protein and antibody collections to the collaboration with researchers in the lab of Sam Hanash. The firm will have rights under the multi-year program to license technologies that result from the collaboration. Further terms of the alliance were not disclosed.

This is Invitrogen's second partnership within the past year aimed at discovering cancer biomarkers. The first, signed in December 2004, is with the Mayo Clinic. Under that collaboration, Invitrogen provides financial and research support for multiple biomarker discovery programs at Mayo, and has an option to license and develop resulting technology on an exclusive and non-exclusive basis.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.